Revvity

Revvity's moat score of 33/100 is notably low for a healthcare equipment company, suggesting limited sustainable competitive advantages. This score largely reflects the profound strategic transformation the company has undergone, specifically the significant divestiture of its Applied, Food, and Enterprise Services (AFES) business.

While the remaining diagnostics and life sciences segments may possess proprietary technologies or intellectual property, the market perceives this restructuring as having diluted or redefined the company's traditional competitive barriers.

The negative 3-year Revenue CAGR of -17.4% strongly indicates this portfolio shrinkage and introduces uncertainty regarding the long-term durability of the new, more focused entity's competitive positioning.

Without stronger barriers to entry, switching costs, or network effects, Revvity may face ongoing pressure from established rivals and new entrants in its core markets.